Skip To Main Content
Paul M Barr on Muck Rack

Paul M Barr

As seen in: Nature, Wiley Online Library, Texas Medical Center, OncLive
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Paul M

Contact Paul M, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Up to 8-Year Follow-Up From RESONATE-2: First-Line Ibrutinib Treatment for Patients With Chronic Lymphocytic Leukemia

|
By Paul M Barr
| Texas Medical Center
Abstract We report long-term follow-up from the RESONATE-2 phase 3 study of the once-daily Bruton's tyrosine kinase inhibitor ibrutinib, which is the only targeted therapy with significant progression-free survival (PFS) and overall survival (OS) benefit in multiple randomized chronic lymphocytic leukemia (CLL) studies.
Open in Who Shared Issue with article?

Treatment of Relapsed/Refractory CLL Patients With PI3Kδ Inhibitor and Anti‐CD20 Antibody Rapidly Decreases Tumor Burden but Could Induce Resistance

|
By Jennifer Bruno, Andrea Baran, Paul M Barr, Alyssa Williams Verified, Sally Quataert, Tim Mosmann, Clive S. Zent, Charles Chu, Christine A. Herne, Karl R. VanDerMeid
| Wiley Online Library Verified
Open in Who Shared Issue with article?

A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia - Leukemia

|
By Christine Ryan, Paul M Barr, Svitlana Tyekucheva, Liam Hackett, Yinglu Zhou, Heather Walker, David Fisher, Jennifer Brown
| Nature Verified
Abstract This study investigated ibrutinib plus obinutuzumab in relapsed/refractory CLL, evaluating tolerability of 3 sequencing regimens as well as overall safety and efficacy. Fifty-two patients were initially randomized 1:1:1 to receive either obinutuzumab 1 month before ibrutinib initiation, ibrutinib 1 month prior to obinutuzumab initiation, or to start both drugs concomitantly.
Open in Who Shared Issue with article?
See all 3 licensed articles (4 Total)